Citations

Mayo Clinic

Clear

128 citation(s) found for "Lafayette, R".

Germline mutations in a G protein identify signaling cross-talk in T cells
Ham, Hyoungjun , Jing, Huie , Lamborn, Ian T. , Kober, M. , Anderson, David E. , Druey, Kirk M. , Mandl, Judith N. , Isidor, Bertrand , Freeman, Alexandra F. , Ganesan, Sundar , Karsak, Meliha , Mustillo, Peter , Teo, Juliana , Zolkipli‐Cunningham, Zarazuela , Lecoquierre, François , Schmid, Jana Pachlopnik , Kuhns, Douglas B. , Xu, Xuehua , Al–Herz, Waleed , Terhal, Paulien A., Muurinen, Mari , Barlogis, Vincent , Danielson, Jeffrey J. , Stewart, Helen , Rading, Sebastian, Keren, Boris , Pfundt, Rolph , Potocki, Lorraine , Olivier, Kenneth N., Faivre, Laurence , Wong, Melanie , Puel, Anne , Chou, Janet , Tusseau, Maud, Moutsopoulos, Niki M. , Matthews, Helen, Simons, Cas , Fink, Danielle , Kong, Heidi H. , Kabát, Juraj , Kim, Woo Sung , Bierhals, Tatjana , Meguro, Kazuyuki , Gu, Jingwen , Stoddard, Jennifer , Banos-Pinero, Benito, Slack, Maria A., Trivellin, Giampaolo , Mazel, Benoît , Li, Samuel T. , Watts, Val J. , Rodriguez-Quevedo, Maria F. , Bruel, Ange‐Line , Lehalle, Daphné , Torres, Daniel , Sullivan, Kathleen E. , Duffourd, Yannis, Similuk, Morgan , Blanc, Pierre , Jin, Tian, Geha, Raif S., Casanova, Jean‐Laurent , Mäkitie, Outi , Edery, Patrick , Germain, Ronald N. , Billadeau, Daniel D. , Zhang, Yu , Lenardo, Michael J. , Kober, Megan M , Koval, Alexey , Anderson, D Eric , Druey, Kirk M , Mandl, Judith N , Isidor, Bertrand , Ferreira, Carlos R , Freeman, Alexandra F , Karsak, Meliha , Mustillo, Peter J , Teo, Juliana , Chatron, Nicolas , Lecoquierre, Francois , Oler, Andrew J , Schmid, Jana Pachlopnik , Kuhns, Douglas B , Xu, Xuehua , Hauck, Fabian , Al-Herz, Waleed , Wagner, Matias , Terhal, Paulien A , Muurinen, Mari , Barlogis, Vincent , Loid, Petra , Keren, Boris , Pfundt, Rolph , Zarember, Kol A , Vill, Katharina , Olivier, Kenneth N , Lesca, Gaetan , Faivre, Laurence , Puel, Anne , Chou, Janet , Moutsopoulos, Niki M , Simons, Cas , Soldatos, Ariane , Masle-Farquhar, Etienne , Pittaluga, Stefania , Brink, Robert , Kong, Heidi H , Kabat, Juraj , Bierhals, Tatjana , Hsu, Amy P. , Gu, Jingwen , Trivellin, Giampaolo , Mazel, Benoît , Soomann, Maarja , Li, Samuel , Watts, Val J , Stratakis, Constantine A , Rodriguez-Quevedo, Maria F , Bruel, Ange-Line , Lipsanen-Nyman, Marita , Saultier, Paul , Lehalle, Daphne , Torres, Daniel , Barbarot, Sébastien , Neu, Axel , Similuk, Morgan N , McWalter, Kirsty , Blanc, Pierre , Bézieau, Stéphane , Geha, Raif S , Casanova, Jean Laurent , Makitie, Outi M , Edery, Patrick , Christodoulou, John , Germain, Ronald N , Goodnow, Christopher C , Sakmar, Thomas P , Billadeau, Daniel D , Kury, Sebastien , Katanaev, Vladimir L , Zhang, Yu , Lenardo, Michael J , Su, Helen C , Berchiche, Yamina A. , Wagner, Matias , Cruz, Phillip , Lesca, Gaëtan , Tusseau, Maud , Taft, Ryan J. , Pittaluga, Stefania , Baños-Piñero, Benito, Stratakis, Constantine A. , Jain, Rashmi, Bezieau, Stéphane , Jin, Tian , Kubisch, Christian , Küry, Sébastien , Su, Helen C.

Science | September 19, 2024 | Volume: 385 | Issue: 6715 | Pages: No page available

10.1126/science.add8947 | PMID 39298586 Get It

Humans with monogenic inborn errors responsible for extreme disease phenotypes can reveal essential physiological pathways. We investigated germline mutations in GNAI2 , which encodes G αi2 , a key component in heterotrimeric G protein signal transduction usually thought to regulate adenylyl cyclase–mediated cyclic adenosine monophosphate (cAMP) production. Patients with activating G αi2 mutations had clinical presentations that included impaired immunity. Mutant G αi2 impaired cell migration and augmented responses to T cell receptor (TCR) stimulation. We found that mutant G αi2 influenced TCR signaling by sequestering the guanosine triphosphatase (GTPase)–activating protein RASA2, thereby promoting RAS activation and increasing downstream extracellular signal–regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)–AKT S6 signaling to drive cellular growth and proliferation.
Evaluation of Interprofessional Delivery of Diabetes Medication Management Training Among Family Medicine Residents
Davis, K.A. , Moore, Elise , Samuelson, Britanee, Stonerock, Lauren R. , Miller, Nathaniel E. , Davis, Amanda, Davis, Katherine , Stonerock, Lauren, Miller, Nathaniel E , Davis, Amanda

Journal of Primary Care & Community Health | September 4, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241276801 | PMID 39228176 Get It

Objective: Diabetes-related care makes up approximately 24% of outpatient clinic visits. Therefore, confidence and understanding of diabetes management is necessary for family medicine residents. Methods: We developed a combined lecture and simulation lab curriculum utilizing a registered nurse and pharmacist to deliver education to 20 family medicine learners. Pre and post surveys of the educational material were completed in 2 sections including one gauging medical knowledge and a second part gauging level of comfort. Results: Of the learners who participated, fourteen completed the pre-post surveys. Most (53%) respondents improved their scores, while 20% scored the same 27% scored worse. The overall average score increased 57% to 70% and improvement was statistically significant ( P < .05). All learners improved confidence by at least 1 point. Conclusion: An interprofessional team utilizing a lecture curriculum focusing on providing education on effective prescribing, medication safety profiles, and resource availability, showed improvement in confidence but mixed knowledge benefit. Further modifications to the curriculum may yield further educational gains.
Rapid detection of IDH mutations in gliomas by intraoperative mass spectrometry
Hua, Wei , Brown, Hannah Marie , Fang, Xinqi , Shahi, Mahdiyeh , Chen, Rong , Jiao, Bin , Wang, Nan , Xu, Hao , Wang, Xiaowen , Zhang, Jinsen , Wang, Qijun , Ye, Dan , Chaichana, Kaisorn L. , Mao, Ying , Quiñones‐Hinojosa, Alfredo , Shahi, Mahdiyeh , Garcia, Diogo Moniz-, Chaichana, Kaisorn, Cooks, R Graham , Quinones-Hinojosa, Alfredo , Zhang, Wenpeng , Wu, Junhan , Zhang, Haoyue , Jiao, Bin, Fu, Minjie , Zhang, Xin , Zhu, Wei Ping , Moniz‐Garcia, Diogo , Cooks, R. Graham , Ouyang, Zheng

Proceedings of the National Academy of Sciences | June 2, 2024 | Volume: 121 | Issue: 23 | Pages: No page available

10.1073/pnas.2318843121 | PMID 38805277 Get It

The development and performance of two mass spectrometry (MS) workflows for the intraoperative diagnosis of isocitrate dehydrogenase (IDH) mutations in glioma is implemented by independent teams at Mayo Clinic, Jacksonville, and Huashan Hospital, Shanghai. The infiltrative nature of gliomas makes rapid diagnosis necessary to guide the extent of surgical resection of central nervous system (CNS) tumors. The combination of tissue biopsy and MS analysis used here satisfies this requirement. The key feature of both described methods is the use of tandem MS to measure the oncometabolite 2-hydroxyglutarate (2HG) relative to endogenous glutamate (Glu) to characterize the presence of mutant tumor. The experiments i) provide IDH mutation status for individual patients and ii) demonstrate a strong correlation of 2HG signals with tumor infiltration. The measured ratio of 2HG to Glu correlates with IDH-mutant (IDH-mut) glioma ( P < 0.0001) in the tumor core data of both teams. Despite using different ionization methods and different mass spectrometers, comparable performance in determining IDH mutations from core tumor biopsies was achieved with sensitivities, specificities, and accuracies all at 100%. None of the 31 patients at Mayo Clinic or the 74 patients at Huashan Hospital were misclassified when analyzing tumor core biopsies. Robustness of the methodology was evaluated by postoperative re-examination of samples. Both teams noted the presence of high concentrations of 2HG at surgical margins, supporting future use of intraoperative MS to monitor for clean surgical margins. The power of MS diagnostics is shown in resolving contradictory clinical features, e.g., in distinguishing gliosis from IDH-mut glioma.
AAPM Task Group 334: A guidance document to using radiotherapy immobilization devices and accessories in an MR environment
Hobson, Maritza A. , Hu, Yanle , Glide‐Hurst, Carri , Jackson, Paul D., Jang, Sunyoung, Narayanan, Sreeram, Park, Justin C., Steffen, John J., Zhou, Yong , Caldwell, Barrett S. , Cohen, Gil’ad N. , Huang, Long , Jang, Sunyoung, Langner, Ulrich W. , Lee, Hannah J. , Levesque, Ives R. , Steffen, John, Wu, Qiuwen , Zhou, Yong

Medical Physics | April 22, 2024 | Volume: 51 | Issue: 6 | Pages: 3822-3849

10.1002/mp.17061 | PMID 38648857 Get It

AbstractUse of magnetic resonance (MR) imaging in radiation therapy has increased substantially in recent years as more radiotherapy centers are having MR simulators installed, requesting more time on clinical diagnostic MR systems, or even treating with combination MR linear accelerator (MR‐linac) systems. With this increased use, to ensure the most accurate integration of images into radiotherapy (RT), RT immobilization devices and accessories must be able to be used safely in the MR environment and produce minimal perturbations. The determination of the safety profile and considerations often falls to the medical physicist or other support staff members who at a minimum should be a Level 2 personnel as per the ACR. The purpose of this guidance document will be to help guide the user in making determinations on MR Safety labeling (i.e., MR Safe, Conditional, or Unsafe) including standard testing, and verification of image quality, when using RT immobilization devices and accessories in an MR environment.
Rituximab or cyclosporine A for the treatment of membranous nephropathy: economic evaluation of the MENTOR trial
So, Helen , Fervenza, Fernando C. , Cattran, Daniel C., Barbour, Sean J. , Investigators, MENTOR Study, Cattran, D C, Appel, Gerald B., Gipson, D, Erickson, Stephen B., Radhakrishnan, Jay, Bomback, A.S., Hogan, Jonathan, Arora, Neha , Nargund, Preeti, Alvarado, Anthony, Hebert, Lee A., Aslam, Nabeel , Porter, Ivan E. , Gipson, Patrick E., Plattner, Brandon L. , Gipson, D, Mariani, Laura , Garg, Pranay, Jefferson, J. Ashley , Nelson, Peter J. , Yarlagadda, Sri G. , Simon, James F. , Gebreselassie, Surafel , Blumenthal, Stanley A., Thomas, L, Cohen, Irvin M., Keddis, Mira T. , Sussman, Andrew L. , Thajudeen, Bijin , Fülöp, Tibor , Craici, Iasmina , Wagner, Steven J., DREISBACH, A, Monga, D., Green, D, Nayer, Ali, Thomas, D. B., Cattran, D C, Reich, Heather N. , Barbour, S. Lee , Philibert, D., Mac‐Way, Fabrice , Desmeules, Simon, Ankawi, Ghada , Sethi, Sanjeev , Ávila-Casado, Carmen , Beanlands, Heather , Fervenza, Fernando C , Kadatz, Matthew , Klarenbach, Scott W , Investigators, MENTOR Study, Cattran, D C, Gipson, D, Kretzler, Matthias , Rovin, Brad H. , Lieske, John C. , Leung, Nelson , Canetta, Pietro A. , Ahn, W, Lafayette, Richard , Arora, N, Parikh, Samir M. , Plattner, B, Gipson, D, Rao, P, Sedor, John R. , O'Toole, J, McCarthy, E, Jain, Namrata Gargee , Rizk, D, Blumenthal, S, Beara‐Lasić, Lada , Zhdanova, Olga A. , Thomas, L, Sussman, A, Juncos, Luis A. , Fulop, T, Monga, D, Mattiazzi, Adela D. , Thomas, D, Barisoni, Laura , Li, T, Vijayan, Anitha , Cattran, D C, Hladunewich, Michelle , Barbour, S, Levin, Adeera , Philibert, D

Nephrology Dialysis Transplantation | April 13, 2024 | Volume: 39 | Issue: 12 | Pages: 2058-2066

10.1093/ndt/gfae084 | PMID 38621719 Get It

ABSTRACT Background and hypothesis The MENTOR trial (MEmbranous Nephropathy Trial Of Rituximab) showed that rituximab was noninferior to cyclosporine in inducing complete or partial remission of proteinuria and was superior in maintaining proteinuria remission. However, the cost of rituximab may prohibit first-line use for some patients and health-care payers. Methods A Markov model was used to determine the incremental cost-effectiveness ratio (ICER) of rituximab compared with cyclosporine for the treatment membranous nephropathy from the perspective of a health-care payer with a lifetime time horizon. The model was informed by data from the MENTOR trial where possible; additional parameters including cost and utility inputs were obtained from the literature. Sensitivity analyses were performed to evaluate the impact of reduced-cost biosimilar rituximab. Results Rituximab for the treatment of membranous nephropathy was cost effective (assuming a willingness-to-pay threshold of $50 000 per quality-adjusted life year (QALY) gained; in $US 2021) compared with cyclosporine, with an ICER of $8373/QALY over a lifetime time horizon. The incremental cost of rituximab therapy was $28 007 with an additional 3.34 QALYs compared with cyclosporine. Lower cost of rituximab biosimilars resulted in a more favorable ICER, and in some cases resulted in rituximab being dominant (lower cost and great benefit) compared to cyclosporine. Conclusions Despite the greater cost of rituximab, it may be a cost-effective option for the treatment of membranous nephropathy when compared with cyclosporine. The cost-effectiveness of rituximab is further improved with the use of less expensive biosimilars.
Radiology-pathology correlation: Giant tumefactive perivascular spaces
Benson, John C. , Trejo‐Lopez, Jorge , Cormier, Jason L, Mark, Ian T. , Madhavan, Ajay A. , Rydberg, Charlotte H. , Eckel, Laurence J. , Trejo-Lopez, Jorge A, Mark, Ian , Madhavan, Ajay A , Kotsenas, Amy L. , Johnson, Derek R , Benson, John , Parney, Ian F. , Luetmer, Patrick H. , Johnson, Derek R.

The Neuroradiology Journal | April 13, 2024 | Volume: 38 | Issue: 2 | Pages: 233-237

10.1177/19714009241247459 | PMID 38613202 Get It

Dilated perivascular spaces (PVSs) are common and easily recognized on imaging. However, rarer giant tumefactive PVSs (GTPVSs) can have unusual multilocular cystic configurations, and are often confused for other pathologic entities, including neoplasms, cystic infarctions, and neuroepithelial cysts. Because GTPVSs are scarcely encountered and even more infrequently operated upon, many radiologists are unaware of the imaging and pathologic features of these lesions. Here, a case of a resected GTPVS is presented, highlighting both its radiologic and histologic characteristics, and discussing how such lesions can be differentiated from their closest mimickers on imaging.
A systematic review and meta‐analysis of diet and nutrient intake in adults with irritable bowel syndrome
Veraza, Diego Izquierdo, Jansson‐Knodell, Claire , Aljaras, Rawan, Biruete, Annabel , Shin, Andrea , Calderon, Gerardo, Shin, Andrea , Calderon-Lopez, Gerardo , Aljaras, Rawan, Foster, Erin D. , Xu, Huiping

Neurogastroenterology & Motility | October 28, 2023 | Volume: 36 | Issue: 1 | Pages: No page available

10.1111/nmo.14698 | PMID 37897138 Get It

AbstractBackgroundNumerous individual and environmental factors including diet may play an important role in the pathophysiology of irritable bowel syndrome (IBS). It is unclear to what degree dietary intake is affected in individuals with IBS. We aimed to perform a systematic review and meta‐analysis to summarize dietary intake of adults with IBS and to compare dietary intake between adults with IBS and non‐IBS controls.MethodsOvid MEDLINE, Embase, Cochrane, CINAHL, and Scopus were searched through February 2023 for clinical trials and observational studies measuring usual diet in adults with IBS. Pooled weighted averages were estimated for total energy, macronutrient, and micronutrient data. Mean differences (MD) in nutrient intake were estimated for adults with IBS versus non‐IBS controls using a random effects model. Heterogeneity was assessed by the inconsistency index (I2).Key ResultsSixty‐three full‐text articles were included in the review of which 29 studies included both IBS and control subjects. Nutrients not meeting the recommended intake level for any dietary reference values in the IBS population were fiber and vitamin D. Meta‐regression by female proportion was positively correlated with total fat intake and negatively correlated with carbohydrate intake. Comparisons between participants with IBS and controls showed significantly lower fiber intake in participants with IBS with high heterogeneity (MD: −1.8; 95% CI: −3.0, −0.6; I2 = 85%).Conclusions and InferencesThis review suggests that fiber and vitamin D intake is suboptimal in IBS; however, overall dietary intake does not appear to be comprised. Causes and consequences of reduced fiber in IBS deserve further study.Results of this systematic review and meta‐analysis suggest that fiber and vitamin D intake is suboptimal in IBS. However, overall intake of other macro‐ and micronutrients does not appear to be compromised. Causes and consequences of reduced fiber and Vitamin D intake in IBS deserve further study.
Does COVID-19 impair V̇o2peak in patients with cardiorespiratory disease? Insight from cardiopulmonary responses to maximal exercise pre- and post-illness
Fernandes, Igor A. , Balavenkataraman, Arvind , BONVIE-HILL, NATALIE , Patel, Neal M. , Helgeson, Scott A. , Bonvie-Hill, Natalie E, Helgeson, Scott A , Taylor, Bryan J.

Journal of Applied Physiology | October 19, 2023 | Volume: 135 | Issue: 5 | Pages: 1146-1156

10.1152/japplphysiol.00357.2023 | PMID 37855032 Get It

There is accumulating evidence that reduced exercise capacity is, or can be, an outcome following COVID-19. However, evidence to date relies upon cross-sectional approaches that either do not consider patients with concomitant cardiorespiratory disease or account for pre-infection exercise capacity data. Accounting for V̇o2peak before COVID-19 and including a group of control patients, we find limited evidence for reduced exercise capacity as a sequela of SARS-CoV-2 infection in patients with concomitant cardiorespiratory disease.
Microglial over-pruning of synapses during development in autism-associated SCN2A-deficient mice and human cerebral organoids
Wu, Jiaxiang , Zhang, Jingliang , Que, Zhefu , Wettschurack, Kyle , Deming, Brody, Cui, Ningren , Zhao, Yuanrui, Halurkar, Manasi , Purba, Mandal, Chen, Ian , Xiao, Tiange , Suzuki, Matthew M., Chen, Fuxue , Wu, Long-Jun , Yang, Yang , Chen, Xiaoling , Acosta, Maria T. , Eaton, Muriel , Suzuki, Matthew, Yuan, Chongli , Xu, Ranjie , Koss, Wendy A. , Du, Dongshu , Wu, Long‐Jun

No container title available | September 28, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3270664/v1 | PMID 37841865 Get It

Abstract Autism spectrum disorder (ASD) is a major neurodevelopmental disorder affecting 1 in 36 children in the United States. While neurons have been the focus to understand ASD, an altered neuro-immune response in the brain may be closely associated with ASD, and a neuro-immune interaction could play a role in the disease progression. As the resident immune cells of the brain, microglia regulate brain development and homeostasis via core functions including phagocytosis of synapses. While ASD has been traditionally considered a polygenic disorder, recent large-scale human genetic studies have identified SCN2A deficiency as a leading monogenic cause of ASD and intellectual disability. We generated a Scn2a-deficient mouse model, which displays major behavioral and neuronal phenotypes. However, the role of microglia in this disease model is unknown. Here, we reported that Scn2a-deficient mice have impaired learning and memory, accompanied by reduced synaptic transmission and lower spine density in neurons of the hippocampus. Microglia in Scn2a-deficient mice are partially activated, exerting excessive phagocytic pruning of post-synapses related to the complement C3 cascades during selective developmental stages. The ablation of microglia using PLX3397 partially restores synaptic transmission and spine density. To extend our findings from rodents to human cells, we established a microglial-incorporated human cerebral organoid model carrying an SCN2A protein-truncating mutation identified in children with ASD. We found that human microglia display increased elimination of post-synapse in cerebral organoids carrying the SCN2A mutation. Our study establishes a key role of microglia in multi-species autism-associated models of SCN2A deficiency from mouse to human cells.